Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application

Pérez-Etcheverry Diana, L. Carmen
{"title":"Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application","authors":"Pérez-Etcheverry Diana, L. Carmen","doi":"10.21013/JAS.V8.N1.P1","DOIUrl":null,"url":null,"abstract":"Aim : To construct an express a mouse-human chimeric antibody against IL-23p19 using a synthetic peptide as immunogen. Methods : Immunization of mice with a synthetic peptide derived from the IL-23p19 sequence and generation of hybridoma secreting specific antibodies. The chimeric antibody was created using two eukaryotic plasmid constructions; one of them carrying the light mouse-human chain and the other the heavy mouse-human chain. CHO-K1 cells were cotransfected with both plasmids and stable transfectants were grown in selective culture medium. Results : A chimeric version of anti-IL-23p19 was successfully constructed and expressed in eukaryotic cells. The expressed chimeric antibody showed specific recognition not only of the peptide used as immunogen but also the subunit p19 and the complete interleukin Il-23. Conclusion : A Chimeric antibody that was developed against a synthetic peptide, which is able to recognize the parent protein IL23 biologically active, could be developed into a targeted therapy in diseases with chronic inflammation.","PeriodicalId":14487,"journal":{"name":"IRA-International Journal of Applied Sciences","volume":"15 1","pages":"1-17"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IRA-International Journal of Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21013/JAS.V8.N1.P1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim : To construct an express a mouse-human chimeric antibody against IL-23p19 using a synthetic peptide as immunogen. Methods : Immunization of mice with a synthetic peptide derived from the IL-23p19 sequence and generation of hybridoma secreting specific antibodies. The chimeric antibody was created using two eukaryotic plasmid constructions; one of them carrying the light mouse-human chain and the other the heavy mouse-human chain. CHO-K1 cells were cotransfected with both plasmids and stable transfectants were grown in selective culture medium. Results : A chimeric version of anti-IL-23p19 was successfully constructed and expressed in eukaryotic cells. The expressed chimeric antibody showed specific recognition not only of the peptide used as immunogen but also the subunit p19 and the complete interleukin Il-23. Conclusion : A Chimeric antibody that was developed against a synthetic peptide, which is able to recognize the parent protein IL23 biologically active, could be developed into a targeted therapy in diseases with chronic inflammation.
IL-23p19合成肽嵌合抗体的产生及其潜在的治疗应用
目的:利用合成的肽段作为免疫原,构建表达人-鼠嵌合抗IL-23p19抗体。方法:用IL-23p19合成肽段免疫小鼠,产生分泌特异性抗体的杂交瘤。利用两个真核质粒构建嵌合抗体;其中一个带着轻的鼠人链,另一个带着重的鼠人链。用两种质粒共转染CHO-K1细胞,并在选择性培养基中培养稳定的转染物。结果:成功构建抗il -23p19嵌合蛋白并在真核细胞中表达。所表达的嵌合抗体不仅能特异性识别作为免疫原的肽,还能识别亚基p19和完整的白细胞介素Il-23。结论:合成的嵌合抗体能够识别具有生物活性的亲本蛋白il - 23,可用于慢性炎症疾病的靶向治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信